• A recombinant humanized mAb directed against the VEGF, a proangiogenic cytokine
    • Binds to VEGF and inhibits receptor binding, thereby preventing the growth and maintenance of tumor blood vessels
    • FDA approved for colon, lung, and renal carcinomas and glioblastoma multiforme
    • Recommended dose: 5 to 10 mg/kg IV every 2 weeks or 15 mg/kg IV every 3 weeks
    • Half-life: 20 days
    • Common side effects: Hypertension, severe or fatal hemorrhage (GI bleed, hemoptysis, CNS bleed), bowel perforation, fistulas/abscess formation, proteinuria
    • Clinical pearls: Have patients monitor blood pressure and bring the log to appointments. Avoid at least 28 days prior to elective surgery and should not be reinitiated for at least 28 days after surgery and until wound is fully healed. Withhold treatment for ≥2 g proteinuria/24 hours and resume when proteinuria is 2 g/24 hours; discontinue in patients with nephrotic syndrome.
    Other topics in Targeted and Immunotherapy Agents